Primary objective: To determine the safety, tolerability and maximumtolerated dose (MTD) of BAY 1129980Secondary objective:To evaluate the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarkers, and tumor response profile of BAY 1129980.
The purpose of this study is to evaluate: - The side effects of BAY1129980 when given every 21 days different dose levels. - Determine the dose level of BAY1129980 that should be tested in future clinical research studies. - Measure how much BAY1129980 is in the blood at specific times after administration. - If treatment with BAY1129980 shows any effect on reducing the tumor growth. - If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not. - If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).